Why United Therapeutics Corporation Stock Skyrocketed

United Therapeutics stock is among today's top gainers after it announces a favorable legal ruling regarding its best-selling drug, Remodulin.

Aug 29, 2014 at 5:08PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of United Therapeutics (NASDAQ:UTHR), a biopharmaceutical company that develops products to treat chronic and life-threatening diseases primarily in the cardiopulmonary field, surged 29% today after receiving a favorable legal decision regarding its lead drug, Remodulin.

So what: According to United Therapeutics' late afternoon press release, the U.S. District Court for the District of New Jersey issued a ruling in favor of United Therapeutics in its patent case against Novartis' (NYSE:NVS) generic drug subsidiary Sandoz International. Sandoz had been planning to bring a generic version of Remodulin, a drug that treats breathing problems in patients with pulmonary arterial hypertension, to market, as noted by its abbreviated new drug application filing in 2011. However, those plans have changed with this ruling that upheld United Therapeutics' exclusivity claims to Remodulin in the U.S. until October 2017.

Now what: The scope of the move higher makes sense from the standpoint of United Therapeutics' shareholders because Remodulin made up $138.2 million, or 43%, of its $322.8 million in sales during the second quarter. This was up 11.1% from the year-ago period. In other words, an unfavorable ruling could have removed about a third of United Therapeutics' revenue within a year, since generics often garner about 80% to 90% of eventual sales from innovator drugs.

The good news here is United Therapeutics is free and clear to continue selling its high-margin lead drug for another three years. On the flipside, investors, or those on the outside looking in and thinking about investing in United Therapeutics, should also realize that its largest drug is going to face generic competition in just over three years. Put plainly, if investors don't have confidence in United Therapeutics' pipeline or other existing products to make up for the eventual loss of exclusivity on Remodulin, then chasing the stock higher after today may not be the best idea.

United Therapeutics may offer plenty of growth potential, but this revolutionary new technology could wind up leaving it in the dust! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers